Develops non-opioid pain therapies for postsurgical and osteoarthritis pain.
Jun 2026Revenue $746M/yrExpenses $726M/yr
No trend
Figures by year
Is Pacira BioSciences profitable?
Yes. In the 12 months to Jun 2026, revenue was $746M and expenses $726M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $726M | $707M | $19.2M |
| Dec 2024 | $701M | $774M | −$73.4M |
| Dec 2023 | $675M | $587M | $87.7M |
| Dec 2022 | $667M | $607M | $60.0M |
| Dec 2021 | $542M | $452M | $89.9M |
| Dec 2020 | $430M | $383M | $46.4M |
| Dec 2019 | $419M | $408M | $10.5M |
| Dec 2018 | $332M | $317M | $15.9M |
| Dec 2017 | $284M | $309M | −$24.9M |
| Dec 2016 | $270M | $302M | −$32.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.